UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Chlorambucil-induced pulmonary injury

Author
Raed A Dweik, MD, FACP, FCCP, FRCP(C), FCCM, FAHA
Section Editors
Kevin R Flaherty, MD, MS
James R Jett, MD
Deputy Editors
Helen Hollingsworth, MD
Diane MF Savarese, MD

INTRODUCTION

Chlorambucil is an alkylating chemotherapy agent. It can be given orally and is mainly used in the treatment of chronic lymphocytic leukemia (CLL). Very rarely, it has been used as an immunosuppressive agent in refractory autoimmune and inflammatory conditions like rheumatoid arthritis and sarcoidosis. (See "Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia", section on 'Chlorambucil-based therapy'.)

Other than myelosuppression, less common side effects of chlorambucil involve the gastrointestinal tract, liver, skin, and the central nervous system; lung toxicity is rare but well documented. Chlorambucil-induced pulmonary injury will be discussed here. A more general discussion of the clinical presentation, diagnosis, and treatment of pulmonary toxicity in patients receiving systemic antineoplastic therapy is presented elsewhere. (See "Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment".)  

INCIDENCE AND RISK FACTORS

While the pulmonary toxicity of other alkylating agents like busulfan and cyclophosphamide is well recognized, chlorambucil-induced pulmonary injury is rare [1]. The literature is confined to isolated case reports [2-19]. The absolute magnitude of risk is undefined. Contemporary clinical trials of chlorambucil in over 600 patients with a hematologic malignancy did not identify any cases of chlorambucil-induced pneumonitis [20-22]. This could be due to the rarity of the phenomenon or to underreporting of events occurring after completion of treatment.

There are no unifying risk factors. Pulmonary toxicity may develop while the patient is taking chlorambucil, or after stopping the drug. There appears to be no direct correlation between the dose or duration of therapy and the incidence of lung toxicity [8]; pulmonary injury has been described in patients receiving cumulative chlorambucil doses ranging from 540 to 8340 mg [5,9].

CLINICAL PRESENTATION

The most common pattern of lung injury reported in chlorambucil treated patients is chronic interstitial pneumonitis (nonspecific interstitial pneumonia, although this nomenclature postdates most reports of chlorambucil lung toxicity), but acute interstitial pneumonia, pulmonary fibrosis, and organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia or BOOP) have also been reported [5-8,11,12,18-20]. Interstitial lung disease may develop while the patient is taking chlorambucil or after stopping it.

            
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Aug 07, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001; 68:782.
  2. Giles FJ, Smith MP, Goldstone AH. Chlorambucil lung toxicity. Acta Haematol 1990; 83:156.
  3. Gentile PS, Woodcock TM, Blumenreich MS, et al. A phase II trial of chlorambucil in non-small cell lung cancer. Am J Clin Oncol 1987; 10:515.
  4. Mohr M, Kingreen D, Rühl H, Huhn D. Interstitial lung disease--an underdiagnosed side effect of chlorambucil? Ann Hematol 1993; 67:305.
  5. Hagmann SG. [Alveolitis and lung fibrosis following therapy with chlorambucil]. Prax Klin Pneumol 1984; 38:108.
  6. Refvem O. Fatal intraalveolar and interstitial lung fibrosis in chlorambucil-treated chronic lymphocytic leukemia. Mt Sinai J Med 1977; 44:847.
  7. Kalambokis G, Stefanou D, Arkoumani E, Tsianos E. Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia. Eur J Haematol 2004; 73:139.
  8. Khong HT, McCarthy J. Chlorambucil-induced pulmonary disease: a case report and review of the literature. Ann Hematol 1998; 77:85.
  9. Crestani B, Jaccard A, Israël-Biet D, et al. Chlorambucil-associated pneumonitis. Chest 1994; 105:634.
  10. Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991; 8:35.
  11. Carr ME Jr. Chlorambucil induced pulmonary fibrosis: report of a case and review. Va Med 1986; 113:677.
  12. Lane SD, Besa EC, Justh G, Joseph RR. Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia. Cancer 1981; 47:32.
  13. Cole SR, Myers TJ, Klatsky AU. Pulmonary disease with chlorambucil therapy. Cancer 1978; 41:455.
  14. McIlvanie SK. Wegener's granulomatosis. Successful treatment with chlorambucil. JAMA 1966; 197:90.
  15. Godard P, Marty JP, Michel FB. Interstitial pneumonia and chlorambucil. Chest 1979; 76:471.
  16. Rose MS. Busulphan toxicity syndrome caused by chlorambucil. Br Med J 1975; 2:123.
  17. Rubio FA Jr. Possible pulmonary effects of alkylating agents. N Engl J Med 1972; 287:1150.
  18. Jacobs, S. The Hamman-Rich syndrome following treatment of lymphoma with chlorambucil. J La State Med Soc 1975; 127:311.
  19. Camus P. The drug-induced respiratory disease website. www.pneumotox.com (Accessed on June 23, 2017).
  20. Shafqat H, Olszewski AJ. Chlorambucil-induced acute interstitial pneumonitis. Case Rep Hematol 2014; 2014:575417.
  21. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370:230.
  22. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31:565.
  23. Vaida I, Roszkiewicz F, Gruson B, et al. Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia. Pharmacology 2009; 83:148.
  24. Tomlinson J, Tighe M, Johnson S, et al. Interstitial pneumonitis following mitozantrone, chlorambucil and prednisolone (MCP) chemotherapy. Clin Oncol (R Coll Radiol) 1999; 11:184.
  25. Hill BT, Weil AC, Kalaycio M, Cook JR. Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration. Leuk Lymphoma 2012; 53:589.
  26. Khanijo S, Tandon P, Sison CP, Koenig S. Thoracic Complications in Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk 2017; 17:220.